Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force
Frank M. Balis, Richard B. Womer, Stacey Berg, Naomi Winick, Peter C. Adamson, Elizabeth Fox
An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA <0.6 m2 and gradually transitions from body weight based to BSA-based dosing.
anticancer drugs
body surface area
Dive into the research topics of 'Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force'. Together they form a unique fingerprint.
Body Surface Area Medicine & Life Sciences 100%
Advisory Committees Medicine & Life Sciences 95%
Body Weight Medicine & Life Sciences 15%
Balis, F. M., Womer, R. B., Berg, S., Winick, N., Adamson, P. C., & Fox, E. (2017). Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. Pediatric Blood and Cancer, 64(11), [e26636]. https://doi.org/10.1002/pbc.26636
Dosing anticancer drugs in infants : Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. / Balis, Frank M.; Womer, Richard B.; Berg, Stacey et al.
In: Pediatric Blood and Cancer, Vol. 64, No. 11, e26636, 11.2017.
Balis, FM, Womer, RB, Berg, S, Winick, N, Adamson, PC & Fox, E 2017, 'Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force', Pediatric Blood and Cancer, vol. 64, no. 11, e26636. https://doi.org/10.1002/pbc.26636
Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E. Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. Pediatric Blood and Cancer. 2017 Nov;64(11):e26636. doi: 10.1002/pbc.26636
Balis, Frank M. ; Womer, Richard B. ; Berg, Stacey et al. / Dosing anticancer drugs in infants : Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. In: Pediatric Blood and Cancer. 2017 ; Vol. 64, No. 11.
@article{db2975d1f28a4eb6a2db810532e1b42d,
title = "Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force",
abstract = "An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA <0.6 m2 and gradually transitions from body weight based to BSA-based dosing.",
keywords = "anticancer drugs, body surface area, dose, infants",
author = "Balis, {Frank M.} and Womer, {Richard B.} and Stacey Berg and Naomi Winick and Adamson, {Peter C.} and Elizabeth Fox",
note = "Funding Information: This study was supported by U10CA180886 and St. Baldrick's Foundation. Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",
T1 - Dosing anticancer drugs in infants
T2 - Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force
AU - Balis, Frank M.
AU - Womer, Richard B.
AU - Berg, Stacey
AU - Winick, Naomi
AU - Adamson, Peter C.
AU - Fox, Elizabeth
N1 - Funding Information: This study was supported by U10CA180886 and St. Baldrick's Foundation. Publisher Copyright: © 2017 Wiley Periodicals, Inc.
N2 - An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA <0.6 m2 and gradually transitions from body weight based to BSA-based dosing.
AB - An analysis of dose modifications for infants in 29 Children's Oncology Group protocols across 10 cancer types revealed 11 sets of criteria defining the infant population using age, weight, body surface area (BSA), or a combination of these parameters and eight dose modification methods. A new method of dosing anticancer drugs in infants was developed based on the rationale that prior modifications were implemented to reduce toxicity, which is not cancer-specific. The new method uses BSA dose banding in dosing tables for infants and children with a BSA <0.6 m2 and gradually transitions from body weight based to BSA-based dosing.
KW - anticancer drugs
KW - body surface area
KW - dose
KW - infants
M1 - e26636